Prospective Grant of Exclusive License: Photosensitizing Antibody-Fluorophore Conjugates for Photo-Immunotherapy, 9678 [2012-3828]
Download as PDF
<![CDATA[
9678
Federal Register / Vol. 77, No. 33 / Friday, February 17, 2012 / Notices
Patent and Trademark Office or the
World Intellectual Property
Organization.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
The
present technology provides a novel
method for cancer therapy which may
offer improved specificity and
sensitivity in cancer treatment. The
method is based on molecular targeting.
More specifically, it is based on
photoimmunotherapy (PIT). The
therapeutic agent is a targeted
photosensitizer composed of a tumor
specific antibody conjugated to IR700
dye, where the dye is sensitive to a near
infrared light. Upon administration of
the conjugated antibody to a subject, it
specifically binds to the targeted
cancerous tissue. Upon subsequent
irradiation with a near infrared light, the
dye releases energy that leads to the
killing of the targeted cells. The concept
was proven by the inventors in vitro and
in vivo with mouse models, using
humanized anti-HER1 (Panitumumab,
for colon cancer), anti-HER2
(Trastuzumab, for breast cancer) and
anti-PSMA antibody (huJ591, for
prostate cancer). Targeted cells were
completely killed while normal cells
were not noticeably affected. The
technology provides also for wearable
LED systems that can be used to
irradiate the photosensitizer.
The prospective exclusive evaluation
option license will comply with the
terms and conditions of 35 U.S.C. 209
and 37 CFR 404.7. The prospective
exclusive evaluation option license may
be granted unless, within fifteen (15)
days from the date of this published
notice, NIH receives written evidence
and argument that establishes that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
SUPPLEMENTARY INFORMATION:
Prospective Grant of Exclusive
License: Photosensitizing AntibodyFluorophore Conjugates for PhotoImmunotherapy
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of a worldwide
exclusive evaluation option license, to
practice the inventions embodied in US
patent application 13/180,111, filed July
11, 2011 (HHS Reference# E–205–2010/
0–US–02), originated from provisional
application 61/363,079 filed July 09,
2010, and entitled ‘‘Photosensitizing
Antibody Fluorophore Conjugates for
Photo-Immunotherapy’’ to Aspyrian
Therapeutics, Inc., a company
incorporated under the laws of the State
of Delaware, having its headquarters in
San Diego, California. The United States
of America is the assignee of the rights
of the above inventions.
The field of use may be limited to
‘‘use of photosensitizing antibodyfluorophore conjugate for imaging and
photo-immunotherapy of cancer’’ and
may be further limited to certain types
of cancer and/or specific platforms.
Upon the expiration or termination of
the exclusive evaluation option license,
Aspyrian Therapeutics, Inc. will have
the right to execute an exclusive
worldwide patent commercialization
license which will supersede and
replace the exclusive evaluation option
license with the same field of use.
DATES: Only written comments and/or
applications for a license received by
the NIH Office of Technology Transfer
on or before March 5, 2012 will be
considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Uri Reichman, Ph.D., M.B.A., Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
4616; Facsimile: (301) 402–0220; Email:
Reichmau@mail.nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published or issued by the United States
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
19:08 Feb 16, 2012
Jkt 226001
Dated: February 13, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2012–3828 Filed 2–16–12; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
Prospective Grant of Exclusive
License: The Development of Human
Anti-CD22 Monoclonal Antibodies for
the Treatment of Human Cancers and
Autoimmune Disease
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
evaluation option license to practice the
inventions embodied in U.S. Patent
Application 61/042,239 entitled
‘‘Human Monoclonal Antibodies
Specific for CD22’’ [HHS Ref. E–080–
2008/0–US–01], PCT Application PCT/
US2009/124109 entitled ‘‘Human and
Improved Murine Monoclonal
Antibodies Against CD22’’ [HHS Ref. E–
080–2008/0–PCT–02], U.S. patent
application 12/934,214 entitled ‘‘Human
Monoclonal Antibodies Specific for
CD22’’ [HHS Ref. E–080–2008/0–US–
03], and all related continuing and
foreign patents/patent applications for
the technology family, to Sanomab, Ltd.
The patent rights in these inventions
have been assigned to and/or
exclusively licensed to the Government
of the United States of America.
The prospective exclusive evaluation
option license territory may be
worldwide, and the field of use may be
limited to:
SUMMARY:
The use of the m971 and m972 (SMB–002)
monoclonal antibodies as therapies for the
treatment of B cell cancers and autoimmune
disease. The Licensed Field of Use includes
the use of the antibodies in the form of an
immunoconjugate, including immunotoxins.
Upon the expiration or termination of
the exclusive evaluation option license,
Sanomab, Ltd. will have the exclusive
right to execute an exclusive
commercialization license which will
supersede and replace the exclusive
evaluation option license with no
greater field of use and territory than
granted in the exclusive evaluation
option license.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before March
5, 2012 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
E:\FR\FM\17FEN1.SGM
17FEN1
]]>Agencies
[Federal Register Volume 77, Number 33 (Friday, February 17, 2012)]
[Notices]
[Page 9678]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-3828]
[[Page 9678]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Photosensitizing
Antibody-Fluorophore Conjugates for Photo-Immunotherapy
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is contemplating the
grant of a worldwide exclusive evaluation option license, to practice
the inventions embodied in US patent application 13/180,111, filed July
11, 2011 (HHS Reference E-205-2010/0-US-02), originated from
provisional application 61/363,079 filed July 09, 2010, and entitled
``Photosensitizing Antibody Fluorophore Conjugates for Photo-
Immunotherapy'' to Aspyrian Therapeutics, Inc., a company incorporated
under the laws of the State of Delaware, having its headquarters in San
Diego, California. The United States of America is the assignee of the
rights of the above inventions.
The field of use may be limited to ``use of photosensitizing
antibody-fluorophore conjugate for imaging and photo-immunotherapy of
cancer'' and may be further limited to certain types of cancer and/or
specific platforms.
Upon the expiration or termination of the exclusive evaluation
option license, Aspyrian Therapeutics, Inc. will have the right to
execute an exclusive worldwide patent commercialization license which
will supersede and replace the exclusive evaluation option license with
the same field of use.
DATES: Only written comments and/or applications for a license received
by the NIH Office of Technology Transfer on or before March 5, 2012
will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Uri Reichman, Ph.D., M.B.A., Office of
Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-
4616; Facsimile: (301) 402-0220; Email: Reichmau@mail.nih.gov. A signed
confidentiality nondisclosure agreement will be required to receive
copies of any patent applications that have not been published or
issued by the United States Patent and Trademark Office or the World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: The present technology provides a novel
method for cancer therapy which may offer improved specificity and
sensitivity in cancer treatment. The method is based on molecular
targeting. More specifically, it is based on photoimmunotherapy (PIT).
The therapeutic agent is a targeted photosensitizer composed of a tumor
specific antibody conjugated to IR700 dye, where the dye is sensitive
to a near infrared light. Upon administration of the conjugated
antibody to a subject, it specifically binds to the targeted cancerous
tissue. Upon subsequent irradiation with a near infrared light, the dye
releases energy that leads to the killing of the targeted cells. The
concept was proven by the inventors in vitro and in vivo with mouse
models, using humanized anti-HER1 (Panitumumab, for colon cancer),
anti-HER2 (Trastuzumab, for breast cancer) and anti-PSMA antibody
(huJ591, for prostate cancer). Targeted cells were completely killed
while normal cells were not noticeably affected. The technology
provides also for wearable LED systems that can be used to irradiate
the photosensitizer.
The prospective exclusive evaluation option license will comply
with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The
prospective exclusive evaluation option license may be granted unless,
within fifteen (15) days from the date of this published notice, NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: February 13, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2012-3828 Filed 2-16-12; 8:45 am]
BILLING CODE 4140-01-P
